About human coagulation factor viii + human von willebrand factor
Plasma-derived coagulation factors
Used for
- Treats and prevents bleeding in von Willebrand disease.
- Treats and prevents bleeding in haemophilia A.
- Supports bleeding control around surgery in these conditions.
Usual adult dose
Individualised by condition, bleeding severity, body weight, laboratory results, and treatment response; given intravenously.
Usual dose in children
Individualised by condition, bleeding severity, body weight, laboratory results, and treatment response; given intravenously.
Common side effects
- Headache or dizziness
- Nausea
- Infusion-site reactions
- Allergic reactions, rarely severe
Important warnings
- Risk of blood clots, particularly with high or repeated doses.
- Factor VIII inhibitors may develop, especially in haemophilia A.
- Allergic reactions can occur; stop infusion and seek urgent care for severe symptoms.
- Plasma-derived products carry a very low residual risk of infectious-agent transmission.
Pregnancy
Use only when clearly needed; evidence is limited. Bleeding risks and treatment needs require specialist assessment.
Breastfeeding
Use only when needed; safety information is limited. Specialist assessment should weigh benefits and risks.
Interactions
- No well-established medicine interactions are known.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.